NO20072199L - Trombopoietinaktivitetsmodulerende forbindelser og fremgangsmater - Google Patents

Trombopoietinaktivitetsmodulerende forbindelser og fremgangsmater

Info

Publication number
NO20072199L
NO20072199L NO20072199A NO20072199A NO20072199L NO 20072199 L NO20072199 L NO 20072199L NO 20072199 A NO20072199 A NO 20072199A NO 20072199 A NO20072199 A NO 20072199A NO 20072199 L NO20072199 L NO 20072199L
Authority
NO
Norway
Prior art keywords
methods
modulating compounds
activity modulating
thrombopoietin activity
thrombopoietin
Prior art date
Application number
NO20072199A
Other languages
English (en)
Inventor
Jyun-Hung Chen
Jackline E Dalgard
Adam E Kallel
Thomas Lau
Matthew H Mcneill
Todd A Miller
Bao Nguyen
Richard J Penulair
Dean P Phillips
Daniel A Ruppar
Lin Zhi
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Publication of NO20072199L publication Critical patent/NO20072199L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Beskrevet heri er substituerte arylhydrazino forbindelser, farmasøytiske sammensetninger som innbefatter det samme, fremgangsmåte for å modulere aktiviteten til en trombopoietin reseptor ved anvendelse av samme, fremgangsmåter for å identifisere forbindelser som trombopoietin reseptor modulatorer og fremgangsmåter for å behandle sykdom ved å administrere en forbindelse ifølge oppfinnelsen til en pasient som trenger det.
NO20072199A 2004-10-25 2007-04-27 Trombopoietinaktivitetsmodulerende forbindelser og fremgangsmater NO20072199L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62187904P 2004-10-25 2004-10-25
US67500105P 2005-04-25 2005-04-25
PCT/US2005/038055 WO2006047344A1 (en) 2004-10-25 2005-10-21 Thrombopoietin activity modulating compounds and methods

Publications (1)

Publication Number Publication Date
NO20072199L true NO20072199L (no) 2007-06-05

Family

ID=35610075

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072199A NO20072199L (no) 2004-10-25 2007-04-27 Trombopoietinaktivitetsmodulerende forbindelser og fremgangsmater

Country Status (15)

Country Link
US (3) US7314887B2 (no)
EP (1) EP1805155B1 (no)
JP (1) JP4728340B2 (no)
KR (1) KR100958337B1 (no)
AR (1) AR051940A1 (no)
AT (1) ATE486859T1 (no)
AU (1) AU2005299720B2 (no)
BR (1) BRPI0516883A (no)
CA (1) CA2583764C (no)
DE (1) DE602005024599D1 (no)
IL (2) IL182763A (no)
MX (1) MX2007004765A (no)
NO (1) NO20072199L (no)
NZ (1) NZ554662A (no)
WO (1) WO2006047344A1 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
WO2006047344A1 (en) * 2004-10-25 2006-05-04 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
CA2630234A1 (en) * 2005-11-23 2007-05-31 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
AU2007329464A1 (en) * 2006-12-01 2008-06-12 Stategics, Inc. Thrombopoietin mimetics
WO2008073864A1 (en) * 2006-12-12 2008-06-19 Smithkline Beecham Corporation Novel combinations
WO2008074078A1 (en) * 2006-12-19 2008-06-26 University Of Wollongong Selectively deliverable isatin-based cytotoxic agents
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
MX2010003881A (es) * 2007-10-09 2010-07-28 Univ Pennsylvania El agonista del receptor de trombopoyetina (tpora) destruye las celulas de leucemia mieloide aguda de humano.
WO2009140464A1 (en) * 2008-05-16 2009-11-19 Ligand Pharmaceuticals, Inc. Methods of administration of thrombopoietin mimetic compounds
US8476249B2 (en) 2009-05-07 2013-07-02 Glaxosmithkline Llc Method of treating thrombocytopenia
US8680150B2 (en) * 2009-05-28 2014-03-25 Ligand Pharmaceuticals, Inc. Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
CN109293551A (zh) 2011-11-14 2019-02-01 利亘制药公司 与粒细胞集落刺激因子受体相关的方法和组合物
US9962370B2 (en) 2013-03-15 2018-05-08 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
CN105744935B (zh) * 2013-11-27 2022-09-30 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
CN106632407A (zh) * 2016-09-30 2017-05-10 陕西科技大学 一种具抗肿瘤活性的不对称双7‑n杂靛红席夫碱类化合物的合成方法
AU2020257272A1 (en) * 2019-04-17 2021-11-11 Colorado Research Partners LLC Novel compounds and methods of use treating fructose-related disorders or diseases

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE193633C (no)
US3148192A (en) 1961-06-27 1964-09-08 Roussel Uclaf Halogenated 20alpha-yohimbane compounds
BE653800A (no)
DE450819C (de) 1924-12-24 1927-10-20 Chemische Ind Ges Verfahren zur Herstellung von chromhaltigen Azofarbstoffen
GB252957A (en) 1926-02-19 1926-06-10 Chem Fab Vormals Sandoz Manufacture of diazotizable azo-dyestuffs and intermediate products therefor
GB898707A (en) 1957-09-20 1962-06-14 Polaroid Corp Dihydroxyphenylketonic compounds and their use in photography
NL255336A (no) 1959-08-29
GB1080864A (en) 1963-02-26 1967-08-23 Ici Ltd Five membered heterocyclic systems and their use as fungicides
GB1269781A (en) 1968-11-12 1972-04-06 Ici Ltd Alkanolamine derivatives
US3966900A (en) 1969-03-12 1976-06-29 Airwick Industries, Inc. Evaporator system comprising a stabilized pesticidal phosphoric acid ester and method for stabilizing such ester enclosed in an evaporator
US3754857A (en) 1969-08-27 1973-08-28 American Cyanamid Co Polyethylene terephthalate,nylon and organic esters of cellulose dyedwith 5-(2-nitro-pranisylazo) barbituric acid
EP0034725B1 (de) 1980-02-18 1984-07-25 BASF Aktiengesellschaft Imidazolylmethylgruppen enthaltende Farbstoffe und deren Verwendung
US4322533A (en) 1980-03-17 1982-03-30 Lesher George Y 1H-Indole-2,3-dione derivatives
DE3329340A1 (de) 1983-08-13 1985-03-07 Basf Ag, 6700 Ludwigshafen Verlackungsmittel enthaltende farbstoffzubereitungen basischer farbstoffe
DE3434379A1 (de) 1984-09-19 1986-03-20 Basf Farben + Fasern Ag, 2000 Hamburg Pigmentzubereitungen
GB8431426D0 (en) * 1984-12-13 1985-01-23 Glaxo Group Ltd Chemical compounds
DE3743235A1 (de) 1987-12-19 1989-06-29 Bayer Ag Basische farbstoffe
DE3810958A1 (de) 1988-03-31 1989-10-12 Basf Ag Tinten fuer ink-jet-aufzeichnungsverfahren
GB8816944D0 (en) 1988-07-15 1988-08-17 Sobio Lab Compounds
JP2683097B2 (ja) 1989-04-28 1997-11-26 キヤノン株式会社 電子写真感光体
US5164404A (en) 1991-03-15 1992-11-17 Neurosearch A/S Hydrazone derivatives and their use
JP2709750B2 (ja) 1991-03-27 1998-02-04 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
US5298658A (en) 1991-12-20 1994-03-29 E. I. Du Pont De Nemours And Company Photographic elements with reduced print-through
DE4335623A1 (de) 1993-10-19 1995-04-20 Henkel Kgaa Indolinon-Derivate zum Färben keratinhaltiger Fasern
US5482546A (en) 1994-03-30 1996-01-09 Canon Kabushiki Kaisha Dye, ink containing the same, and ink-jet recording method and instrument using the ink
EP0675201A1 (en) 1994-03-31 1995-10-04 Amgen Inc. Compositions and methods for stimulating megakaryocyte growth and differentiation
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
US6075044A (en) 1997-07-21 2000-06-13 The Regents Of The University Of California Heterocyclic derivatives as inhibitors of purine salvage phosphoribosyltransferases
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6649631B1 (en) 1997-10-23 2003-11-18 The Board Of Regents Of The University Of Texas System Compositions and methods for treating bone deficit conditions
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
JP2000206645A (ja) 1999-01-18 2000-07-28 Fuji Photo Film Co Ltd 画像形成材料および画像形成方法
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
AU6023300A (en) 1999-07-26 2001-02-13 Shionogi & Co., Ltd. Drug compositions exhibiting thrombopoietin agonism
AU770564B2 (en) 1999-09-10 2004-02-26 Smithkline Beecham Corporation Thrombopoietin mimetics
JP2003509462A (ja) 1999-09-24 2003-03-11 スミスクライン・ビーチャム・コーポレイション トロンボポイエチン模倣物
US6720345B1 (en) 1999-11-05 2004-04-13 Smithkline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
JP2001152055A (ja) 1999-11-26 2001-06-05 Fuji Photo Film Co Ltd インクジェット記録用インクおよびそれを用いた画像記録方法
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
JP4359382B2 (ja) 2000-07-11 2009-11-04 富士フイルム株式会社 新規なヒドラゾン色素
JP2004517049A (ja) 2000-09-01 2004-06-10 グラクソ　グループ　リミテッド チロシンキナーゼ阻害剤としての置換オキシインドール誘導体
AU8664701A (en) 2000-09-01 2002-03-22 Glaxo Group Ltd Oxindole derivatives
US6642265B1 (en) 2000-09-08 2003-11-04 Smithkline Beecham Corporation Thrombopoietin mimetics
JP2002129073A (ja) 2000-10-20 2002-05-09 Fuji Photo Film Co Ltd 油性インク組成物
JP2002129072A (ja) 2000-10-20 2002-05-09 Fuji Photo Film Co Ltd インクジェット記録用インク及びそれを用いた画像記録方法
US7241783B2 (en) 2000-12-19 2007-07-10 Smithkline Beecham Corporation Thrombopoietin mimetics
US20040053299A1 (en) 2000-12-21 2004-03-18 Delorme Evelyn O. Regulated activation of cell-membrane receptors by metal-chelating agonists
EP1361220A4 (en) 2001-01-26 2005-09-07 Shionogi & Co CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM
US6875786B2 (en) 2001-03-01 2005-04-05 Smithkline Beecham Corporation Thrombopoietin mimetics
ATE497603T1 (de) 2001-03-02 2011-02-15 Gpc Biotech Ag Drei-hybrid-assaysystem
GB0106343D0 (en) 2001-03-14 2001-05-02 Avecia Ltd Compounds compositions and processes
US7825104B2 (en) 2001-07-23 2010-11-02 Ramot At Tel Aviv University Ltd. Methods and compositions for treating fungal infections
US6916798B2 (en) 2001-08-03 2005-07-12 Vertex Pharmaceuticals Incorporated Inhibitors of GSK-3 and uses thereof
JP2003128946A (ja) 2001-10-26 2003-05-08 Fuji Photo Film Co Ltd 新規なアゾ色素、及び該アゾ色素の互変異性体
GB0126036D0 (en) 2001-10-30 2001-12-19 Amedis Pharm Ltd Silicon compounds
CN1319967C (zh) 2002-01-18 2007-06-06 安斯泰来制药有限公司 2－酰基氨基噻唑衍生物或其盐
WO2003074497A1 (en) 2002-03-01 2003-09-12 Pintex Pharmaceutical, Inc. Pin1-modulating compounds and methods of use thereof
US20040002537A1 (en) 2002-03-29 2004-01-01 Zamvil Scott S. Use of statins in the treatment of autoimmune disease
US20030229453A1 (en) 2002-04-09 2003-12-11 Antonysamy Stephen Suresh Crystals and structures of PAK4KD kinase PAK4KD
JP2003313450A (ja) 2002-04-22 2003-11-06 Fuji Photo Film Co Ltd アゾ色素及びその互変異性体
JP2003335972A (ja) 2002-05-21 2003-11-28 Fuji Photo Film Co Ltd アゾ化合物及びその製造方法
MY142390A (en) 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
JP4562523B2 (ja) 2002-06-06 2010-10-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー トロンボポエチン疑似体
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
JP2004143118A (ja) 2002-10-28 2004-05-20 Fuji Photo Film Co Ltd アゾ化合物及びその互変異性体、並びに、その製造方法
JP2006514951A (ja) 2002-12-13 2006-05-18 スミスクライン・ビーチャム・コーポレイション トロンボポエチン模倣物
US20040253178A1 (en) 2002-12-20 2004-12-16 Shane Atwell Crystals and structures of spleen tyrosine kinase SYKKD
JP4895807B2 (ja) 2003-04-29 2012-03-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 変性疾患／損傷の治療方法
WO2004105587A2 (en) * 2003-05-28 2004-12-09 Medcool, Inc. Methods and apparatus for thermally activating a console of a thermal delivery system
UA82695C2 (uk) 2003-06-06 2008-05-12 Нисан Кемикал Индастриз, Лтд. Гетероароматичні сполуки як активатори рецептора тромбопоетину
CA2563316A1 (en) 2004-04-06 2005-10-20 Semafore Pharmaceuticals, Inc. Pten inhibitors
EA012602B1 (ru) 2004-05-12 2009-10-30 Байер Кропсайенс Аг Регулирование роста растений
WO2005118551A2 (en) 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
SE0401790D0 (sv) 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
WO2006047344A1 (en) 2004-10-25 2006-05-04 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
GT200500321A (es) 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
WO2006076442A2 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives
CA2630234A1 (en) 2005-11-23 2007-05-31 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
US20070162307A1 (en) 2006-01-11 2007-07-12 Austin Gary M Toolbar user interface for information system

Also Published As

Publication number Publication date
CA2583764C (en) 2009-06-09
IL182763A0 (en) 2007-07-24
ATE486859T1 (de) 2010-11-15
US7314887B2 (en) 2008-01-01
AR051940A1 (es) 2007-02-21
EP1805155A1 (en) 2007-07-11
AU2005299720B2 (en) 2010-02-04
US7691895B2 (en) 2010-04-06
IL182763A (en) 2010-12-30
KR100958337B1 (ko) 2010-05-17
EP1805155B1 (en) 2010-11-03
AU2005299720A1 (en) 2006-05-04
US20080146594A1 (en) 2008-06-19
JP4728340B2 (ja) 2011-07-20
IL191542A0 (en) 2008-11-03
NZ554662A (en) 2008-11-28
DE602005024599D1 (de) 2010-12-16
IL191542A (en) 2013-08-29
BRPI0516883A (pt) 2008-09-23
MX2007004765A (es) 2007-07-09
US20060116417A1 (en) 2006-06-01
JP2008517932A (ja) 2008-05-29
US20080103190A1 (en) 2008-05-01
KR20070084506A (ko) 2007-08-24
WO2006047344A1 (en) 2006-05-04
CA2583764A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
NO20072199L (no) Trombopoietinaktivitetsmodulerende forbindelser og fremgangsmater
NO20064362L (no) Forbindelser, farmaseutiske sammensetninger og fremgangsmater for anvendelse i behandling av metabolske sykdommer
WO2007062078A3 (en) Thrombopoietin activity modulating compounds and methods
NO20071054L (no) Metoder og blandinger for a modulere sfingosin-l-fosfat (sip) reseptoraktivitet
NO20061074L (no) Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20081975L (no) Diarylamin-inneholdende forbindelser og sammensetninger, og deres anvendelse som modulatorer av C-kit-reseptorer
EA200900959A1 (ru) Ингибиторы мек
BRPI0518222A (pt) composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
NO20070907L (no) Pyrrolo-pyridin kinase modulatorer
NO20073665L (no) 2-fenoksy-N-(1,3,4-tiadizol-2-yl) Pyridin-3-aminderivater og beslektede forbindelser som P2Y1 reseptor inhibitorer for behandling av tromboemboliforstyrrelser
DK2212283T3 (da) Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
NO20063191L (no) Aminobenzazoler som P2Y1-reseptorinhibitorer
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
EA200700489A1 (ru) Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
DK2212282T3 (da) Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
NO20064344L (no) Caspaseinhibitorer og anvendelser derav
MY148807A (en) Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
WO2008041140A8 (en) Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application